BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26529313)

  • 1. 18F-FDG PET-CT after Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients to Optimize Surgical Decision Making.
    Anderegg MC; de Groof EJ; Gisbertz SS; Bennink RJ; Lagarde SM; Klinkenbijl JH; Dijkgraaf MG; Bergman JJ; Hulshof MC; van Laarhoven HW; van Berge Henegouwen MI
    PLoS One; 2015; 10(11):e0133690. PubMed ID: 26529313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Computerized Tomography (PET-CT) Scan in Identifying Interval Metastases for Patients with Esophageal Cancer.
    Gabriel E; Alnaji R; Du W; Attwood K; Kukar M; Hochwald S
    Ann Surg Oncol; 2017 Jun; 24(6):1739-1746. PubMed ID: 28058562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detecting Interval Distant Metastases With 18F-FDG PET/CT After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Cancer.
    Kroese TE; Ruurda JP; Bakker AS; Jairam J; Mook S; van der Horst S; Meijer GJ; Haj Mohammad N; van Rossum PSN; van Hillegersberg R
    Clin Nucl Med; 2022 Jun; 47(6):496-502. PubMed ID: 35384907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer.
    Stiekema J; Vermeulen D; Vegt E; Voncken FE; Aleman BM; Sanders J; Boot H; van Sandick JW
    Clin Nucl Med; 2014 Oct; 39(10):862-7. PubMed ID: 25140549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis.
    Kroese TE; Goense L; van Hillegersberg R; de Keizer B; Mook S; Ruurda JP; van Rossum PSN
    Dis Esophagus; 2018 Dec; 31(12):. PubMed ID: 29917073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
    JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of
    Sasaki K; Uchikado Y; Okumura H; Omoto I; Kita Y; Arigami T; Uenosono Y; Owaki T; Maemura K; Natsugoe S
    Anticancer Res; 2017 Feb; 37(2):859-864. PubMed ID: 28179343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of (18)F-FDG PET/CT methods of analysis for predicting response to neoadjuvant chemoradiation therapy in patients with locally advanced low rectal cancer.
    Altini C; Niccoli Asabella A; De Luca R; Fanelli M; Caliandro C; Quartuccio N; Rubini D; Cistaro A; Montemurro S; Rubini G
    Abdom Imaging; 2015 Jun; 40(5):1190-202. PubMed ID: 25348731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy.
    Bruzzi JF; Swisher SG; Truong MT; Munden RF; Hofstetter WL; Macapinlac HA; Correa AM; Mawlawi O; Ajani JA; Komaki RR; Fukami N; Erasmus JJ
    Cancer; 2007 Jan; 109(1):125-34. PubMed ID: 17146785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of Response to Neoadjuvant Chemotherapy and Radiation Therapy with Baseline and Restaging
    Beukinga RJ; Hulshoff JB; Mul VEM; Noordzij W; Kats-Ugurlu G; Slart RHJA; Plukker JTM
    Radiology; 2018 Jun; 287(3):983-992. PubMed ID: 29533721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incremental value of 18F-FDG PET/CT in therapeutic decision-making of potentially curable esophageal adenocarcinoma.
    Purandare NC; Pramesh CS; Karimundackal G; Jiwnani S; Agrawal A; Shah S; Kulkarni M; Laskar SG; Rangarajan V
    Nucl Med Commun; 2014 Aug; 35(8):864-9. PubMed ID: 24751701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of post-neoadjuvant therapy PET-CT in the detection of interval metastases in esophageal carcinoma.
    Blom RL; Schreurs WM; Belgers HJ; Oostenbrug LE; Vliegen RF; Sosef MN
    Eur J Surg Oncol; 2011 Sep; 37(9):774-8. PubMed ID: 21726976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation-induced liver injury mimicking liver metastases on FDG-PET-CT after chemoradiotherapy for esophageal cancer : A retrospective study and literature review.
    Voncken FEM; Aleman BMP; van Dieren JM; Grootscholten C; Lalezari F; van Sandick JW; Steinberg JD; Vegt E
    Strahlenther Onkol; 2018 Feb; 194(2):156-163. PubMed ID: 29051991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy.
    Cerfolio RJ; Bryant AS; Ohja B; Bartolucci AA; Eloubeidi MA
    J Thorac Cardiovasc Surg; 2005 Jun; 129(6):1232-41. PubMed ID: 15942562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of
    Valkema MJ; Noordman BJ; Wijnhoven BPL; Spaander MCW; Biermann K; Lagarde SM; Bennink RJ; Schreurs WMJ; Roef MJ; Hobbelink MGG; Janssen MJR; Graven LH; van Lanschot JJB; Valkema R
    J Nucl Med; 2019 Nov; 60(11):1553-1559. PubMed ID: 30877177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Cancer Using
    Borggreve AS; Goense L; van Rossum PSN; Heethuis SE; van Hillegersberg R; Lagendijk JJW; Lam MGEH; van Lier ALHMW; Mook S; Ruurda JP; van Vulpen M; Voncken FEM; Aleman BMP; Bartels-Rutten A; Ma J; Fang P; Musall BC; Lin SH; Meijer GJ
    Int J Radiat Oncol Biol Phys; 2020 Apr; 106(5):998-1009. PubMed ID: 31987972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction and diagnosis of interval metastasis after neoadjuvant chemoradiotherapy for oesophageal cancer using
    Goense L; Ruurda JP; Carter BW; Fang P; Ho L; Meijer GJ; van Hillegersberg R; Hofstetter WL; Lin SH
    Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1742-1751. PubMed ID: 29663014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study.
    Borggreve AS; Mook S; Verheij M; Mul VEM; Bergman JJ; Bartels-Rutten A; Ter Beek LC; Beets-Tan RGH; Bennink RJ; van Berge Henegouwen MI; Brosens LAA; Defize IL; van Dieren JM; Dijkstra H; van Hillegersberg R; Hulshof MC; van Laarhoven HWM; Lam MGEH; van Lier ALHMW; Muijs CT; Nagengast WB; Nederveen AJ; Noordzij W; Plukker JTM; van Rossum PSN; Ruurda JP; van Sandick JW; Weusten BLAM; Voncken FEM; Yakar D; Meijer GJ;
    BMC Cancer; 2018 Oct; 18(1):1006. PubMed ID: 30342494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The benefit of PET/CT in the diagnosis and treatment of esophageal cancer.
    Vomackova K; Neoral C; Aujeský R; Vrba R; Stasek M; Myslivecek M; Formánek R
    Rozhl Chir; 2015 Jan; 94(1):8-16. PubMed ID: 25604979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?
    Cuellar SL; Carter BW; Macapinlac HA; Ajani JA; Komaki R; Welsh JW; Lee JH; Swisher SG; Correa AM; Erasmus JJ; Hofstetter WL
    J Thorac Oncol; 2014 Aug; 9(8):1202-6. PubMed ID: 25157774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.